Predictive value of GGN and CAG repeat polymorphisms of androgen receptors in testicular cancer: a meta-analysis

Jiang, Wenhua; Zhang, Jing; Zhou, Qing; Liu, Shuaimei; Ni, Mengxia; Zhu, Peiran; Wu, Qiuyue; Li, Weiwei; Zhang, Mingchao; Xia, Xinyi

doi:10.18632/oncotarget.7337

Cited by 10 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through literature search and collection based on inclusion and exclusion criteria, we found 12 qualified publications after checking possibly relevant articles ( Jiang et al, 2016 ). Fig.…”

Section: Resultsmentioning

confidence: 99%

Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiple sclerosis risk: A meta-analysis

Liu

et al. 2016

Meta Gene

View full text Add to dashboard Cite

PurposeMultiple sclerosis (MS) is a major demyelinating disease of the central nervous system with a strong genetic component. Previous studies have reported that the association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with the susceptibility to MS. However, the results were inconsistent. Thus, we conducted this meta-analysis to provide a more accurate estimation of the association between any of these polymorphisms and MS risk.MethodsThe PubMed, Embase, Chinese National Knowledge Infrastructure, Wan Fang databases and MSGene were used to search all potentially relevant studies. The odds ratio (OR) with 95% confidence interval (CI) was used to investigate the associations between these three polymorphisms and MS risk.Results16 independent case–control studies from 12 publications were finally included into this meta-analysis. The results showed that EVI5 rs11808092 polymorphism was related with increasing the development of MS under five genetic models (allelic: OR = 1.17, 95% CI = 1.10–1.24, P < 0.01; homozygous: OR = 1.37, 95% CI = 1.18–1.59, P < 0.01; heterozygous: OR = 1.16, 95% CI = 1.07–1.26, P < 0.01; recessive: OR = 1.28, 95% CI = 1.11–1.48, P < 0.01; and dominant: OR = 1.19, 95% CI = 1.11–1.48, P < 0.01). CD58 rs2300747 polymorphism was found to be associated with decreasing MS risk in three genetic models (allelic: OR = 0.86, 95% CI = 0.78–0.94, P < 0.01; heterozygous: OR = 0.85, 95% CI = 0.76–0.94, P < 0.01, and dominant: OR = 0.84, 95% CI = 0.76–0.93, P < 0.01). However, this meta-analysis indicated that CIITA rs3087456 polymorphism was not related to multiple sclerosis.ConclusionsThe mutant alleles of EVI5 rs11808092 polymorphism may increase the susceptibility to MS while those of CD58 rs2300747 polymorphism may decrease MS risk. In addition, CIITA rs3087456 polymorphism might not be associated with MS.

show abstract

Section: Resultsmentioning

confidence: 99%

Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiple sclerosis risk: A meta-analysis

Liu

et al. 2016

Meta Gene

View full text Add to dashboard Cite

show abstract

“…We also carried out sensitivity analysis in which a single study within the overall meta‐analysis was deleted one at a time. We applied Funnel plots and Egger's linear regression test to assess publication bias (Chung et al., ; Jiang et al., ; Salvo et al., ; Upala & Sanguankeo, ). All statistical analyses were carried out using STATA version 11.0 (Stata Corporation College Station, TX, USA).…”

Section: Methodsmentioning

confidence: 99%

“…The strength of association between the two most common SNPs and the risk of male infertility were assessed by odds ratio (OR) with 95% confidence intervals (CI) (Jiang et al., ). The statistical significance of the pooled OR was determined with the Z‐test, with p ‐values <.05 considered to be statistically significant.…”

Section: Methodsmentioning

confidence: 99%

Systematic review and meta‐analysis of the genetic association between protamine polymorphism and male infertility

et al. 2018

View full text Add to dashboard Cite

While several previous studies have proposed an association between male infertility and protamine polymorphism, the reported findings have shown some inconsistency. To evaluate the potential association between the two most common single nucleotide polymorphisms (rs2301365 and rs1646022) in protamine and male infertility, we performed a meta-analysis involving 2713 cases and 2086 controls from 15 published case-controlled studies. Overall, our analysis showed significant associations between the specific protamine single-nucleotide polymorphism (rs2301365) and male infertility, and this association was indicated by all of the models we tested. Subgroup analysis revealed significant associations with a Caucasian background, PCR sequence, population-based, case size of > 150 and case size of < 150 subgroups. Similarly, significant associations were found between rs1646022 and male infertility in the hospital population and case size of < 200 subgroups. However, trial sequential analysis showed that the number of patients in the study did not reach optimal information size. Further studies with larger sample sizes are now warranted to clarify the potential roles of the two protamine polymorphisms in the pathogenesis of male infertility. This may help us to understand the precise molecular mechanisms underlying the effect of protamines upon male infertility.

show abstract

“…Much of our understanding of androgen regulation of angiogenesis has been obtained in cancer studies. Androgens and androgen signalling are implicated in many human cancer types, including prostate [34,35], testicular germ cell [36] and bladder [37] cancers. Androgens are also known to have complex roles in breast tumors [38][39][40].…”

Section: Androgens Angiogenesis and Cancermentioning

confidence: 99%

Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development

et al. 2017

View full text Add to dashboard Cite

The placenta and tumors share important characteristics, including a requirement to establish effective angiogenesis. In the case of the placenta, optimal angiogenesis is required to sustain the blood flow required to maintain a successful pregnancy, whereas in tumors establishing new blood supplies is considered a key step in supporting metastases. Therefore the development of novel angiogenesis inhibitors has been an area of active research in oncology. A subset of the molecular processes regulating angiogenesis are well understood in the context of both early placentation and tumorigenesis. In this review we focus on the well-established role of androgen regulation of angiogenesis in cancer and relate these mechanisms to placental angiogenesis. The physiological actions of androgens are mediated by the androgen receptor (AR), a ligand dependent transcription factor. Androgens and the AR are essential for normal male embryonic development, puberty and lifelong health. Defects in androgen signalling are associated with a diverse range of clinical disorders in men and women including disorders of sex development (DSD), polycystic ovary syndrome in women and many cancers. We summarize the diverse molecular mechanisms of androgen regulation of angiogenesis and infer the potential significance of these pathways to normal and pathogenic placental function. Finally, we offer potential research applications of androgen-targeting molecules developed to treat cancer as investigative tools to help further delineate the role of androgen signalling in placental function and maternal and offspring health in animal models.

show abstract

Predictive value of GGN and CAG repeat polymorphisms of androgen receptors in testicular cancer: a meta-analysis

Cited by 10 publications

References 38 publications

Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiple sclerosis risk: A meta-analysis

Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiple sclerosis risk: A meta-analysis

Systematic review and meta‐analysis of the genetic association between protamine polymorphism and male infertility

Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development

Contact Info

Product

Resources

About